annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 24D Phase II, two-arm, double-blind, multicenter, randomized study of the
combination of oral WX-671 plus capecitabine versus capecitabine in
first-line HER2-negative metastatic breast cancer (MBC). (Abstract #TPS131)
L. J. Goldstein, S. M. Stemmer, B. Schmalfeldt, N. Gottschalk, F. Cardoso, H.
Dushkin, C. Mala, N. Uebler, P. Bevan, N. Harbeck
Brd. 24E TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts)
with HER2� metastatic breast cancer (MBC). (Abstract #TPS132)
N. U. Lin, I. A. Mayer, T. J. Hobday, C. I. Falkson, E. C. Dees, R. Nanda, I. E. Krop,
M. F. Rimawi, A. C. Wolff, E. P. Winer, on behalf of the Translational Breast Cancer
Research Consortium (TBCRC)
Brd. 24F Three parallel randomized phase II trials of dasatinib plus hormone therapy
(HT) in advanced ER� breast cancer (ER� ABC). (Abstract #TPS133)
L. C. Strauss, J. O’Shaughnessy, J. Jackson, D. Paul, G. L. Wright, A. Rybicki, A.
Goldhirsch
Brd. 24G A phase II comparative study of metformin plus first-line chemotherapy (CT)
versus CT alone in HER2-negative, insulin-resistant (IR), nondiabetic
metastatic breast cancer (MBC). (Abstract #TPS134)
A. Gennari, O. Nanni, P. Bruzzi, A. De Censi, U. Pfeffer, R. Zamarchi, M. Maglie, L.
Gianni, D. Amadori
Brd. 24H A phase II randomized trial of lapatinib with either vinorelbine or
capecitabine in ErbB2-overexpressing first- and second-line metastatic
breast cancer (MBC). (Abstract #TPS135)
W. Janni, J. V. Álvarez, C. A. Papadimitriou, B. Karaszewska, W. Wiest, M. L. Lim,
A. Das-Gupta
Brd. 25A A randomized multicenter phase II trial of capecitabine versus S-1 as firstline
treatment in unresectable or recurrent breast cancer patients. (Abstract
#TPS136)
D. Yamamoto, S. Iwase, H. Odagiri, Y. Kuroda, K. Akazawa, K. Kitamura, T.
Kawaguchi, C. Yamamoto, Y. Nagumo, N. Sakata
Brd. 25B Comparison of zoledronic acid retention in bone of multiple myeloma and
breast cancer patients: Consequences for efficacy? (Abstract #TPS137)
K. Søe, J. Delaisse, E. H. Jakobsen, H. B. Jørgensen, T. Plesner
Brd. 25F Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to
breast cancer chest wall recurrences or skin metastases. (Abstract #TPS138)
S. Adams, Z. Dewan, T. Meng, J. D. Goldberg, A. Tiersten, N. Bhardwaj, S.
Formenti, S. Demaria
Cancer Prevention/Epidemiology
Brd. 25G Utilization of 5HTT-gene polymorphism as a prognostic indicator in cancer.
(Abstract #TPS139)
N. M. Awad, M. Farouk, H. Elshafei, S. Ghobashy, M. Elbordiny, A. A. Elsaid, A.
Omar
Brd. 25H Fish oil, green tea, and prostate cancer prevention. (Abstract #TPS140)
J. Shannon, S. Lieberman, C. Maxcy, P. Thuillier, L. Peters, M. Garzotto
Brd. 26A A randomized trial of atorvastatin versus placebo in women at high risk for
breast cancer. (Abstract #TPS141)
M. E. Wood, F. Kingsley, J. A. Ellerton, J. N. Atkins, S. S. Grubbs, H. B. Muss, J. E.
Garber
Brd. 26B Phase IB randomized, double-blinded, placebo-controlled, dose-escalation
study of polyphenon E in women with a history of hormone
receptor-negative breast cancer. (Abstract #TPS142)
K. D. Crew, P. Brown, H. Greenlee, T. B. Bevers, B. Arun, C. Hudis, H. L.
McArthur, L. Vornik, T. L. Cornelison, D. L. Hershman, Phase I/II Chemoprevention
Trials Consortium
Brd. 26F Sulforaphane supplementation in women newly diagnosed with DCIS: A
biomarker study. (Abstract #TPS143)
J. Shannon, E. Ho, A. Naik, M. Troxell, A. Cox, C. Maxcy, J. T. Vetto
317
MONDAY